New studies suggest that a high level of Vitamin D in the blood may improve
our mood during the winter months, and may also protect against colds and
flu.
This is my discovery of the season! I’ve already written about the
importance of maintaining a strong level of vitamin D3 in the blood, to protect
against cancer. This works in cancer prevention, but it’s also very likely to
have an impact in slowing the progress of cancer. We’re now learning that women
with a high level of vitamin D3 have the lowest risk of developing breast
cancer, and that if they do develop cancer, they have a lower risk of cancer
progression (Abbas et al. 2009 ; Goodwin, 2008).
This beneficial effect of vitamin D3 seems likely to extend to
non-small-cell lung cancer too.
In one study, people with the highest blood
levels of vitamin D3 had an average survival rate that was double those who had
the lowest blood levels of vitamin D3 (Zhou et al., 2005). Similar data also
exists for cancers of the colon and prostate cancers (Freedman et al. 2007, Woo
et al., 2005).
Indeed, researchers into vitamin D believe that it slows the progress of all
forms of cancer, at least during its early phases (Cannell et Hollis,
2008).
What’s new is that it seems that adequate levels of vitamin D3 -- comparable
to the levels observed during the summer months in people who enjoy moderate
exposure to the sun – may also protect from colds and winter flu (Laaksi et
al., 2007), and may additionally contribute to maintaining a positive mood,
acting as a kind of antidote to falling energy levels during the cold, dark
winter months (Wilkins et al. 2006).
Two doctors of integrative medicine have
recently published an article on the subject (Cannell and Hollis, 2008), and
they conclude that we should maintain our blood-levels of vitamin D3 above 50
ng/ml (in Europe, where this is usually measured in nmol/l, this corresponds to
about 125 nmol/l) and below 70 ng/ml (175 nmol/l). (To convert ng/ml to nmol/l,
multiply by 2.498).
You should note that, in the absence of large-scale, long-term research into
survival rates, Dr Jean-Claude Souberbielle, who has been studying vitamin D
for 25 years at the Necker Hospital in Paris, recommends a blood level above 30
ng/ml (roughly 90 nmol/l), and under 50 ng/ml (125 nmol/l), in order to
minimize the risk of side-effects such as the development of developing kidney
stones due to excessive absorption of calcium.
The best way to move forward on this is to talk to your doctor about the
importance of analyzing your level of vitamin D3. (Many doctors do this
regularly, but others have no knowledge of this field). You may also need to
take appropriate supplements. Vitamin D experts recommend taking daily
supplements of 1,000 – 5,000 International Units (remember that our skin
manufactures 10,000 IU after 15 to 20 minutes of exposure to midday sun in the
summer), or single doses of 100,000 units of vitamin D3, once or twice a month
(each dose costs no more than $1.50). However, it’s usually better NOT to take
ergocalciferol (also known as vitamin D2), which some experts think may be more
toxic.
RISKS The only possible risks associated with excessive intake of vitamin D3
– particularly in people who have cancer – are, firstly, that kidney stones may
develop due to excessive calcium in the urine, and, secondly, hypercalcemia
(excessive levels of calcium in the bloodstream). Hypercalcemia may in some
cases be lethal to people with cancer. It is therefore recommended that you
measure blood levels of vitamin D3 (25 OH cholecalciferol) and calcium, before
you begin supplements, and roughly every three months during treatment.
Acknowledgment Thanks to Thierry Souccar and his team at www.lanutrition.fr
for having alerted me to the recent article by Cannell and Hollis.
Bibliography:
Souberbielle J-C, Prié D, Couberbaisse M, et al. News on the
effects of vitamin D and the evaluation of vitamin D status. Annals of
Endocrinology 2008;69:501-10. Abbas S, Chang-Claude J, Linseisen J. Plasma
25-hydroxyvitamin D and premenopausal breast cancer risk in a German
case-control study. Int J Cancer 2009;124(1):250-5.
Goodwin PJ. Frequency of
vitamin D (Vit D) deficiency at breast cancer (BC) diagnosis and association
with risk of distant recurrence and death in a prospective cohort study of
T1-3, N0-1, M0 BC. In: Annual Meeting of the American Society of Clinical
Oncology; 2008.
Zhou W, Suk R, Liu G, et al. Vitamin D is associated with
improved survival in early-stage non-small cell lung cancer patients. Cancer
Epidemiology, Biomarkers & Prevention 2005;14(10):2303-9.
Freedman DM,
Looker AC, Chang S-C, Graubard BI. Prospective Study of Serum Vitamin D and
Cancer Mortality in the United States. J Natl Cancer Inst
2007;99(21):1594-602.
Woo TCS, Choo R, Jamieson M, Chander S, Vieth R. Pilot
study: potential role of vitamin D (Cholecalciferol) in patients with PSA
relapse after definitive therapy. Nutr Cancer 2005;51(1):32-6.
Cannell JJ,
Hollis BW. Use of vitamin D in clinical practice. Altern Med Rev 2008;13.
Laaksi I, Ruohola J-P, Tuohimaa P, et al. An association of serum vitamin D
concentrations < 40 nmol/L with acute respiratory tract infection in young
Finnish men. American Journal of Clinical Nutrition 2007;86(3):714-7.
Wilkins
CH, Sheline YI, Roe CM, Birge SJ, Morris JC. Vitamin D deficiency is associated
with low mood and worse cognitive performance in older adults. American Journal
of Geriatric Psychiatry 2006;14(12):1032-40.